129. ESMO 2024 - Day 3

Day three of the European Society of Medical Oncology Congress had many exciting and potentially practice-changing trials in the genitourinary space. Gone are the days of urothelial cancer having a single treatment and prostate cancer only having androgen deprivation therapy.They look at biomarkers for ADC response in bladder cancer, the use of lutetium upfront for metastatic hormone-sensitive prostate cancer, and novel ADC use in metastatic urothelial carcinoma.Links to studies discussed in this episode (subscription may be required):DV001 (Disitamab vedotin (DV) + pembrolizumab in treatment-naïve HER2-expressing LA/met UC)EV-302 - nectin four expressionUpFrontPSMA StudySplash Study (Lu-PNT2002)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.SplashDisitimab Vedotin Hosted on Acast. See acast.com/privacy for more information.